Evidence map›Paper›PMID 35158951›Full record

ArticleCancers2022

Masaya Ono, Yoichi Sunagawa, Saho Mochizuki, Takahiro Katagiri, Hidemichi Takai, Sonoka Iwashimizu, Kyoko Inai, Masafumi Funamoto, Kana Shimizu, Satoshi Shimizu and 9 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 12 citations in OpenAlex.

  1. Hydrogen Protection Boosts the Bioactivity ofAntioxidants (Basel, Switzerland) · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 3 institutions in 1 country.

Masaya OnoDivision of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka 422-8526, Japan.
Yoichi SunagawaDivision of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka 422-8526, Japan.ORCID 0000-0002-4516-2308
Saho MochizukiDivision of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka 422-8526, Japan.
Takahiro KatagiriDivision of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka 422-8526, Japan.
Hidemichi TakaiDivision of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka 422-8526, Japan.
Sonoka IwashimizuDivision of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka 422-8526, Japan.
Kyoko InaiDivision of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka 422-8526, Japan.
Masafumi FunamotoDivision of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka 422-8526, Japan.
Kana ShimizuDivision of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka 422-8526, Japan.
Satoshi ShimizuDivision of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka 422-8526, Japan.ORCID 0000-0001-8363-564X
Yasufumi KatanasakaDivision of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka 422-8526, Japan.ORCID 0000-0002-1755-2157
Maki KomiyamaDivision of Translational Research, Clinical Research Institute, Kyoto Medical Center, National Hospital Organization, Kyoto 612-8555, Japan.ORCID 0000-0002-8827-3315
Philip HawkeLaboratory of Scientific English, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka 422-8526, Japan.
Hideo HaraUNIAL Co., Ltd., Tokyo 173-0005, Japan.
Yoshiki ArakawaDepartment of Neurosurgery, Kyoto University Graduate of Medicine, Kyoto 606-8507, Japan.ORCID 0000-0003-4626-4645
Kiyoshi MoriShizuoka General Hospital, Shizuoka 420-8527, Japan.ORCID 0000-0002-7285-8351
Akira AsaiCenter for Drug Discovery, Graduate School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka 422-8526, Japan.
Koji HasegawaDivision of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka 422-8526, Japan.
Tatsuya MorimotoDivision of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka 422-8526, Japan.
University of Shizuoka · JPKyoto Medical Center · JPKyoto University · JP

Funding

Japan Science and Technology Agency 18K08121Japan Science and Technology Agency 19K16396Japan Science and Technology Agency 20K07070
6 · The paper itself

Abstract

It is well known that the anthracycline anticancer drug doxorubicin (DOX) induces cardiotoxicity. Recently,

Indexed as

apoptosiscardiomyopathyChrysanthemum morifoliumdoxorubicinp53systolic dysfunction

Identifiers

PMID35158951
PMCPMC8833354
OpenAlexW4210733930

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.